Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Icopezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icopezil SCHEMBL2231222 | 1.00 | ACHE (1.00) | ACHEBCHE | |
| Icopezil SCHEMBL9276204 | 0.96 | ACHE (0.93) | ACHEBCHE | |
| Icopezil SCHEMBL9276199 | 0.96 | ACHE (0.93) | ACHEBCHE | |
| Icopezil SCHEMBL194482 | 0.94 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL4512593 | 0.91 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL2402320 | 0.89 | ACHE (0.90) | ACHEBCHE | |
| Maleic Acid SCHEMBL3926936 | 0.87 | ACHE (0.77) | ACHEBCHE | |
| SCHEMBL220485 | 0.87 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL2405514 | 0.86 | ACHE (0.84) | ACHEBCHE | |
| SCHEMBL2403486 | 0.85 | ACHE (0.82) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. | 2022-05-26 | — | — | US | claimed |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-20250275985-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | AMYLYX PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | Amylyx Pharmaceuticals Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220110948-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | AMYLYX PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20140099366-A1 | Composition Containing Two Anti-Dementia Drugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8507527-B2 | Method for stabilizing anti-dementia drug | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8481565-B2 | Rivastigmine, galantamine, donepezil; ethylcellulose high molecular weight basic water-insoluble polymer; methacrylic acid-ethyl acrylate high molecular weight acidic enteric polymer; succinic acid, ascorbic acid low molecular weight anti-oxidant; sustained-release base prevent, inhibit degradation | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20100152164-A1 | Method For Stabilizing Anti-Dementia Drug | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20090023778-A1 | Composition Containing Anti-Dementia Drug | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20020064500-A1 | Radiotracers for in vivo study of acetylcholinesterase and alzheimer's disease | FROST J JAMES (US) | 2002-05-30 | — | — | US | disclosed |
| US-6372760-B1 | COGNITION ACTIVATORS WITH ORGANIC ACID FOR DONEPEZIL | EISAI CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | VILLALOBOS ANABELLA (US) | 2002-03-07 | — | — | US | disclosed |
| US-6326382-B1 | CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE | EISAI CO., LTD (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-1086706-A1 | STABILIZED COMPOSITIONS CONTAINING NOOTROPIC DRUGS | Eisai Co., Ltd. (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-1048302-A2 | Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease | Pfizer Products Inc. (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-0947193-A2 | Percutaneously applicable preparation and suppository containing an antidementia medicament | Eisai Co., Ltd. (JP) | 1999-10-06 | — | — | EP | disclosed |
| US-5538984-A | Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors | PFIZER INC. (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | ACHE 3040/4885BCHE 531/4885 |
| US-20250275985-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | ACHE 3040/4885BCHE 531/4885 |
| US-20220110948-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | ACHE 3040/4885BCHE 531/4885 |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | BCHE, ACHE, CHRM1 | ACHE 2/4885BCHE 1/4885 |
| US-20020064500-A1 | Radiotracers for in vivo study of acetylcholinesterase and alzheimer's disease | ACHE, BCHE, CHAT | ACHE 1/4885BCHE 2/4885 |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACHE, CHAT, BACE1 | ACHE 1/4885BCHE 34/4885 |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | HSPA9, CYP27A1, TUFM | ACHE 3040/4885BCHE 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.